NORA SAUL: Open Payments
NPI 1801132014 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,737 in 63 payments from 14 companies in 2025. Trend: 2023 $2,713 · 2024 $591 · 2025 $1,737
Food & beverage: $1,737
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 22 | $544 |
| SK Life Science, Inc. | 6 | $278 |
| Biogen, Inc. | 3 | $176 |
| JAZZ PHARMACEUTICALS INC. | 5 | $147 |
| Inspire Medical Systems, Inc. | 1 | $128 |
| Neurelis, Inc. | 4 | $116 |
| Lundbeck LLC | 4 | $78 |
| Abbott Laboratories | 3 | $66 |
| Aucta Pharmaceuticals, Inc. | 9 | $62 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
Products named: Fintepla, TYSABRI, EPIDIOLEX, INSPIRE, Nayzilam, XCOPRI, VALTOCO, VYEPTI.
Industry payments across AZ — which companies pay providers there.
